Vincent D. De Jager

Groningen, GR, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Corrigendum to "Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands" [Eur J Cancer 205 (2024)114125].

Corrigendum to "Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands" [Eur J Cancer 205 (2024)114125].

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 25, 2026

Large language model-based approach for low-cost, rapid and accurate automated extraction of predictive biomarker testing results from Dutch pathology reports.

Large language model-based approach for low-cost, rapid and accurate automated extraction of predictive biomarker testing results from Dutch pathology reports.

Journal: Virchows Archiv : an international journal of pathology

Published: August 21, 2025

Real-world evidence of RET fusion prevalence and testing in patients with metastatic non-small cell lung cancer.

Real-world evidence of RET fusion prevalence and testing in patients with metastatic non-small cell lung cancer.

Journal: Translational oncology

Published: August 15, 2025

Fostering the implementation of liquid biopsy in clinical practice: meeting report 2024 of the European Liquid Biopsy Society (ELBS).

Fostering the implementation of liquid biopsy in clinical practice: meeting report 2024 of the European Liquid Biopsy Society (ELBS).

Journal: Journal of experimental & clinical cancer research : CR

Published: February 11, 2025

Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop.

Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop.

Journal: EBioMedicine

Published: October 09, 2024

Prognostic Value of KRAS/TP53 Status for Overall Survival in First-Line Monoimmunotherapy and Chemoimmunotherapy Treated Patients With Nonsquamous NSCLC in the Netherlands: A Brief Report.

Prognostic Value of KRAS/TP53 Status for Overall Survival in First-Line Monoimmunotherapy and Chemoimmunotherapy Treated Patients With Nonsquamous NSCLC in the Netherlands: A Brief Report.

Journal: JTO clinical and research reports

Published: July 22, 2024

Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy.

Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy.

Journal: ESMO open

Published: May 24, 2024

Detection of actionable mutations in circulating tumor DNA for non-small cell lung cancer patients.

Detection of actionable mutations in circulating tumor DNA for non-small cell lung cancer patients.

Journal: Communications medicine

Published: April 05, 2024

Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands.

Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands.

Journal: European journal of cancer (Oxford, England : 1990)

Published: January 15, 2024

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib.

Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib.

Journal: NPJ precision oncology

Published: January 08, 2024

Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer.

Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer.

Journal: The Lancet regional health. Europe

Published: September 15, 2023

Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries.

Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries.

Journal: The Lancet regional health. Europe

Published: August 29, 2023

Showing 1-12 of 16

Last Updated: 09/26/2026